兽药活性药物成分製造市场 - 全球产业规模、份额、趋势、机会和预测，按服务类型、按合成类型、按动物类型、按治疗类别、按地区和竞争，2019-2029F

2023 年，全球兽药活性药物成分製造市场估值为83.9 亿美元，预计在预测期内将出现令人印象深刻的增长，到2029 年，复合年增长率为7.12%。 ) 製造市场是一个关键领域在更广泛的製药行业中，致力于生产兽药的基本化合物。该市场以动物健康和福利为重点，在确保有效治疗和预防各种动物物种（包括牲畜、宠物和伴侣动物）的疾病方面发挥着至关重要的作用。兽用原料药的需求是由动物疾病盛行率不断上升、宠物拥有率上升以及对食品安全和品质日益关注等因素所推动的。因此，製药公司、合约製造商和研究机构不断创新并投资于高品质兽用原料药的开发和生产。从地理上看，该市场涵盖全球，主要参与者分布在北美、欧洲、亚太地区和拉丁美洲等地区。技术进步、监管架构和经济因素显着影响市场动态，塑造生产流程、供应链和定价策略。此外，合作、併购和收购是公司为巩固市场地位和扩大产品组合所采取的常见策略。永续发展和环境议题也越来越受到关注，促使製造商探索生态友善的生产方法并投资于绿色措施。

市场概况
预测期	2025-2029
2023 年市场规模	83.9亿美元
2029 年市场规模	125.5亿美元
2024-2029 年复合年增长率	7.12%
成长最快的细分市场	伴侣动物
最大的市场	北美洲

主要市场驱动因素

提高宠物拥有率

动物疾病盛行率上升

主要市场挑战

成本限制

供应链中断

主要市场趋势

扩大伴侣动物药品市场

兽用生物製药的出现

细分市场洞察

合成类型见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球兽药活性药物成分製造市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依服务类型（内部、合约外包）
  • 依合成类型（化学原料药、生物原料药、HPAPI）
  • 依动物类型（生产动物、伴侣动物）
  • 依治疗类别（抗寄生虫药、抗感染药、非类固醇抗发炎药、其他）
  • 按公司划分 (2023)
  • 按地区
• 市场地图

第 6 章：北美兽药活性药物成分製造市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按服务类型
  • 按合成类型
  • 依动物类型
  • 按治疗类别
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 7 章：欧洲兽药活性药物成分製造市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按服务类型
  • 按合成类型
  • 依动物类型
  • 按治疗类别
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第 8 章：亚太地区兽药原料药製造市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按服务类型
  • 按合成类型
  • 依动物类型
  • 按治疗类别
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第 9 章：南美洲兽药活性药物成分製造市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按服务类型
  • 按合成类型
  • 依动物类型
  • 按治疗类别
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲兽药活性药物成分製造市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按服务类型
  • 按合成类型
  • 依动物类型
  • 按治疗类别
  • 按国家/地区
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第14章：竞争格局

• Zoetis Inc.
• Alivira Animal Health Limited
• Ofichem Group
• Chempro Group
• Siflon Group
• Qilu Animal Health Products Co., Ltd.
• Chemo Holding, SL
• SUAN FARMA SAU
• MENADIONA
• Excel Industries Ltd

第 15 章：策略建议

第16章调查会社について・免责事项

Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market was valued at USD 8.39 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.12% through 2029. The Global Veterinary Active Pharmaceutical Ingredients (API) Manufacturing market is a crucial segment within the broader pharmaceutical industry, dedicated to producing essential compounds for veterinary medications. With a focus on animal health and welfare, this market plays a vital role in ensuring the effective treatment and prevention of diseases in various animal species, including livestock, pets, and companion animals. The demand for veterinary APIs is driven by factors such as the increasing prevalence of animal diseases, rising pet ownership rates, and growing concerns regarding food safety and quality. As a result, pharmaceutical companies, contract manufacturers, and research institutions are continuously innovating and investing in the development and production of high-quality veterinary APIs. Geographically, the market exhibits a global presence, with key players operating in regions such as North America, Europe, Asia Pacific, and Latin America. Technological advancements, regulatory frameworks, and economic factors significantly influence market dynamics, shaping production processes, supply chains, and pricing strategies. Moreover, collaborations, mergers, and acquisitions are common strategies adopted by companies to strengthen their market position and expand their product portfolios. Sustainability and environmental concerns are also gaining traction, prompting manufacturers to explore eco-friendly production methods and invest in green initiatives.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 8.39 Billion
Market Size 2029	USD 12.55 Billion
CAGR 2024-2029	7.12%
Fastest Growing Segment	Companion Animals
Largest Market	North America

Key Market Drivers

Increasing Pet Ownership Rates

Increasing pet ownership rates worldwide are significantly boosting the Global Veterinary Active Pharmaceutical Ingredients (API) Manufacturing Market. As more households welcome pets into their families, the demand for veterinary medications rises correspondingly. Pets, including dogs, cats, birds, and small mammals, are increasingly regarded as integral members of the family, prompting pet owners to invest in their health and well-being. This cultural shift towards viewing pets as companions rather than mere animals has led to a surge in spending on pet care products and services, including veterinary medicines.

The rise in pet ownership rates is driven by various factors, including urbanization, changing lifestyles, and an increasing awareness of the positive impact of pets on mental and emotional well-being. In urban areas, where space constraints and busy lifestyles often discourage traditional pet ownership, there is a growing trend towards owning smaller pets such as cats, birds, and small mammals that require less space and are more adaptable to apartment living. Additionally, the COVID-19 pandemic has accelerated the trend of pet ownership, with many individuals seeking companionship and emotional support during periods of social isolation and uncertainty.

As the number of pets worldwide continues to grow, so does the demand for veterinary medications to treat and prevent diseases. Veterinary APIs form the backbone of these medications, serving as the active ingredients that deliver therapeutic effects. Pharmaceutical companies are thus ramping up production of veterinary APIs to meet this escalating demand. They are investing in research and development to develop new and improved formulations that address a wide range of health concerns in pets, from common ailments like fleas and ticks to more serious conditions such as diabetes and cancer.

The increasing focus on preventive healthcare for pets is driving demand for veterinary APIs used in the production of vaccines, flea and tick preventatives, and other preventive medications. Pet owners are increasingly proactive about keeping their pets healthy and preventing diseases before they occur, leading to a growing market for preventive veterinary medicines. In response, pharmaceutical companies are developing innovative vaccines and preventive treatments that target a broad spectrum of diseases, further fueling growth in the veterinary API manufacturing market.

Rising Prevalence of Animal Diseases

The rising prevalence of animal diseases is a significant driver behind the burgeoning Global Veterinary Active Pharmaceutical Ingredients (API) Manufacturing Market. Across the globe, there has been an alarming increase in the incidence of infectious and non-infectious diseases affecting various animal species, including livestock, companion animals, and wildlife. This trend poses significant challenges to animal health, welfare, and food security, prompting a surge in demand for veterinary medications and vaccines.

In the agriculture and livestock sectors, diseases such as foot-and-mouth disease, avian influenza, African swine fever, and bovine respiratory disease can have devastating effects on animal populations and agricultural economies. These diseases not only cause suffering and mortality in affected animals but also result in significant economic losses due to reduced productivity, trade restrictions, and control measures. As a result, there is a growing urgency to develop effective preventive and therapeutic solutions to combat these diseases, driving demand for veterinary APIs used in their formulation.

The increasing globalization of trade and travel has facilitated the spread of infectious diseases among animal populations, making disease control and prevention efforts more challenging. Emerging zoonotic diseases, which can be transmitted from animals to humans, further underscore the importance of addressing animal health issues. Governments, regulatory agencies, and international organizations are thus prioritizing efforts to strengthen disease surveillance, outbreak response, and biosecurity measures to mitigate the spread of animal diseases. In response to these challenges, pharmaceutical companies are ramping up production of veterinary APIs used in the production of vaccines, antimicrobial agents, parasiticides, and other veterinary medicines. These APIs serve as the active ingredients that deliver therapeutic effects, helping to prevent, control, and treat a wide range of animal diseases. Additionally, there is a growing demand for diagnostic tests, biosecurity products, and veterinary healthcare services aimed at detecting and managing disease outbreaks in animals.

The rising prevalence of animal diseases is driving innovation in the veterinary pharmaceutical industry, leading to the development of new and improved therapies for animal health. Pharmaceutical companies are investing in research and development to develop novel drug formulations, vaccine technologies, and diagnostic tools to address emerging disease threats and meet the evolving needs of the market.

Key Market Challenges

Cost Constraints

Cost constraints are a major challenge for manufacturers in the Global Veterinary API Manufacturing Market. Developing and manufacturing veterinary APIs involves significant investments in research and development, raw materials, manufacturing processes, and quality assurance. Additionally, the market for veterinary medicines is relatively smaller compared to the human pharmaceutical market, limiting economies of scale and increasing production costs. Moreover, pricing pressures from competition, generic alternatives, and government reimbursement policies can further squeeze profit margins for manufacturers. Balancing the need for affordable veterinary medicines with the costs of production presents a significant challenge for industry players.

Supply Chain Disruptions

Supply chain disruptions pose a significant challenge to the Global Veterinary API Manufacturing Market. The industry relies on a complex network of suppliers, contract manufacturers, distributors, and logistics providers to source raw materials, manufacture APIs, and deliver finished products to customers. Disruptions in the supply chain, such as natural disasters, geopolitical tensions, transportation bottlenecks, or raw material shortages, can disrupt production schedules, lead to inventory shortages, and impact product availability. Additionally, the COVID-19 pandemic highlighted vulnerabilities in global supply chains, further exacerbating challenges related to sourcing, production, and distribution of veterinary APIs.

Key Market Trends

Expansion of Companion Animal Pharmaceutical Market

The global veterinary active pharmaceutical ingredients (API) manufacturing market is experiencing significant growth, propelled by the expanding companion animal pharmaceutical market. Companion animals, including dogs, cats, and horses, have become integral parts of households worldwide, leading to a surge in demand for specialized veterinary medicines tailored to their unique healthcare needs. As pet ownership continues to rise globally, so does the expenditure on companion animal healthcare. Pet owners are increasingly investing in preventive healthcare measures, diagnostics, and advanced treatment options to ensure the health and well-being of their beloved pets. This growing emphasis on pet healthcare has spurred the development and commercialization of a wide range of veterinary pharmaceuticals, driving the demand for high-quality active pharmaceutical ingredients.

One of the key factors driving the expansion of the companion animal pharmaceutical market is the humanization of pets. Pet owners increasingly view their animals as family members and are willing to spend more on their healthcare needs. This shift in perception has led to the development of specialized veterinary medicines targeting conditions such as arthritis, cancer, diabetes, and behavioral disorders in companion animals. Consequently, pharmaceutical companies are investing heavily in research and development to create innovative veterinary APIs tailored to address these specific therapeutic areas.

Advancements in veterinary medicine, including novel drug delivery systems and biopharmaceuticals, are driving the growth of the companion animal pharmaceutical market. Biotechnology-derived drugs, such as monoclonal antibodies and recombinant proteins, offer promising treatment options for various diseases in companion animals, further fueling market expansion.

The globalization of the companion animal pharmaceutical industry is also contributing to the growth of the veterinary API manufacturing market. Pharmaceutical companies are expanding their presence in emerging markets to capitalize on the growing demand for veterinary medicines. Moreover, strategic collaborations, partnerships, and acquisitions are reshaping the competitive landscape of the industry, driving innovation and market growth.

Emergence of Biopharmaceuticals for Veterinary Use

The emergence of biopharmaceuticals for veterinary use is reshaping the landscape of the global veterinary active pharmaceutical ingredients (API) manufacturing market. Biopharmaceuticals, derived from biological sources such as living cells or organisms, offer novel treatment options for various diseases in animals, driving significant growth in the veterinary pharmaceutical sector. Biopharmaceuticals for veterinary use encompass a wide range of products, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapies. These innovative therapies provide targeted and efficacious treatments for conditions ranging from infectious diseases to chronic illnesses in companion animals and livestock.

Primary drivers behind the adoption of biopharmaceuticals in veterinary medicine is their ability to address unmet medical needs and offer superior therapeutic outcomes compared to traditional pharmaceuticals. Monoclonal antibodies, for example, can specifically target disease-causing agents with high precision, minimizing adverse effects and improving treatment efficacy. Similarly, recombinant proteins offer targeted therapeutic interventions for conditions such as hormone deficiencies and immune disorders in animals.

The development of biopharmaceuticals for veterinary use is supported by advancements in biotechnology and genetic engineering. Cutting-edge technologies enable the production of complex biological molecules in large quantities, making biopharmaceuticals more accessible and cost-effective for veterinary applications. Additionally, ongoing research in areas such as gene editing and regenerative medicine holds promise for the development of innovative biopharmaceutical therapies for veterinary use.

The globalization of the veterinary pharmaceutical industry is also driving the growth of the veterinary API manufacturing market for biopharmaceuticals. Pharmaceutical companies are expanding their portfolios to include biotechnology-derived veterinary medicines, leveraging their expertise in bioprocessing and regulatory compliance to meet the growing demand for advanced veterinary therapies worldwide.

Segmental Insights

Synthesis Type Insights

In the Global Veterinary Active Pharmaceutical Ingredients (API) Manufacturing Market, the chemical-based API segment has emerged as the dominant player based on synthesis type. Chemical-based APIs have a long-established presence in the pharmaceutical industry, offering a wide range of compounds that are essential for the formulation of veterinary medicines. Their extensive use and proven efficacy make them a preferred choice for pharmaceutical manufacturers. Chemical synthesis allows for the production of APIs in large quantities at relatively low costs, making them commercially viable for mass production. This scalability is crucial in meeting the growing demand for veterinary medicines worldwide.

Futhermore, biological API segment is anticipated to grow at the fastest rate in the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market. advancements in biotechnology have paved the way for the development of novel biological APIs tailored for veterinary use. Biopharmaceuticals derived from living organisms offer targeted and efficacious treatment options for a wide range of animal diseases, driving demand for biological APIs.

Regional Insights

In 2023, North America asserted its dominance in the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market, largely due to a convergence of several key factors. Firstly, the region boasts a robust infrastructure for pharmaceutical manufacturing, with advanced research and development capabilities and stringent regulatory standards that ensure high-quality production. This creates an environment conducive to innovation and product development, allowing North American companies to stay at the forefront of the veterinary API market.

North America is home to a significant concentration of leading pharmaceutical companies specializing in veterinary medicines. These companies leverage their extensive resources, expertise, and networks to drive growth and maintain a competitive edge in the global market. The region benefits from a strong veterinary healthcare system and a growing pet population, particularly in the United States and Canada. This increases the demand for veterinary pharmaceuticals, including active pharmaceutical ingredients, driving the growth of the market in North America.

Key Market Players

Zoetis Inc.

Alivira Animal Health Limited

Ofichem Group

Chempro Group

Siflon Group

Qilu Animal Health Products Co., Ltd.

Chemo Holding, S.L

SUAN FARMA S.A.U

MENADIONA

Excel Industries Ltd

Report Scope:

In this report, the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Service Type:

In House Contract Outsourcing

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Synthesis Type:

Chemical-based API Biological API HPAPI

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Animal Type:

Production Animals Companion Animals

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Therapeutic Category:

Antiparasitic Anti-infectives NSAIDs Others

Veterinary Active Pharmaceutical Ingredients Manufacturing Market, By Region:

North America
• United States
• Canada
• Mexico
Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
South America
• Brazil
• Argentina
• Colombia
Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market.

Available Customizations:

Global Veterinary Active Pharmaceutical Ingredients Manufacturing market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service Type (In House, Contract Outsourcing)
  • 5.2.2. By Synthesis Type (Chemical-based API, Biological API, HPAPI)
  • 5.2.3. By Animal Type (Production Animals, Companion Animals)
  • 5.2.4. By Therapeutic Category (Antiparasitic, Anti-infectives, NSAIDs, Others)
  • 5.2.5. By Company (2023)
  • 5.2.6. By Region
• 5.3. Market Map

6. North America Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service Type
  • 6.2.2. By Synthesis Type
  • 6.2.3. By Animal Type
  • 6.2.4. By Therapeutic Category
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service Type
      • 6.3.1.2.2. By Synthesis Type
      • 6.3.1.2.3. By Animal Type
      • 6.3.1.2.4. By Therapeutic Category
  • 6.3.2. Mexico Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service Type
      • 6.3.2.2.2. By Synthesis Type
      • 6.3.2.2.3. By Animal Type
      • 6.3.2.2.4. By Therapeutic Category
  • 6.3.3. Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service Type
      • 6.3.3.2.2. By Synthesis Type
      • 6.3.3.2.3. By Animal Type
      • 6.3.3.2.4. By Therapeutic Category

7. Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service Type
  • 7.2.2. By Synthesis Type
  • 7.2.3. By Animal Type
  • 7.2.4. By Therapeutic Category
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service Type
      • 7.3.1.2.2. By Synthesis Type
      • 7.3.1.2.3. By Animal Type
      • 7.3.1.2.4. By Therapeutic Category
  • 7.3.2. Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service Type
      • 7.3.2.2.2. By Synthesis Type
      • 7.3.2.2.3. By Animal Type
      • 7.3.2.2.4. By Therapeutic Category
  • 7.3.3. United Kingdom Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service Type
      • 7.3.3.2.2. By Synthesis Type
      • 7.3.3.2.3. By Animal Type
      • 7.3.3.2.4. By Therapeutic Category
  • 7.3.4. Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service Type
      • 7.3.4.2.2. By Synthesis Type
      • 7.3.4.2.3. By Animal Type
      • 7.3.4.2.4. By Therapeutic Category
  • 7.3.5. Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service Type
      • 7.3.5.2.2. By Synthesis Type
      • 7.3.5.2.3. By Animal Type
      • 7.3.5.2.4. By Therapeutic Category

8. Asia-Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service Type
  • 8.2.2. By Synthesis Type
  • 8.2.3. By Animal Type
  • 8.2.4. By Therapeutic Category
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service Type
      • 8.3.1.2.2. By Synthesis Type
      • 8.3.1.2.3. By Animal Type
      • 8.3.1.2.4. By Therapeutic Category
  • 8.3.2. India Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service Type
      • 8.3.2.2.2. By Synthesis Type
      • 8.3.2.2.3. By Animal Type
      • 8.3.2.2.4. By Therapeutic Category
  • 8.3.3. South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service Type
      • 8.3.3.2.2. By Synthesis Type
      • 8.3.3.2.3. By Animal Type
      • 8.3.3.2.4. By Therapeutic Category
  • 8.3.4. Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service Type
      • 8.3.4.2.2. By Synthesis Type
      • 8.3.4.2.3. By Animal Type
      • 8.3.4.2.4. By Therapeutic Category
  • 8.3.5. Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service Type
      • 8.3.5.2.2. By Synthesis Type
      • 8.3.5.2.3. By Animal Type
      • 8.3.5.2.4. By Therapeutic Category

9. South America Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service Type
  • 9.2.2. By Synthesis Type
  • 9.2.3. By Animal Type
  • 9.2.4. By Therapeutic Category
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service Type
      • 9.3.1.2.2. By Synthesis Type
      • 9.3.1.2.3. By Animal Type
      • 9.3.1.2.4. By Therapeutic Category
  • 9.3.2. Argentina Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service Type
      • 9.3.2.2.2. By Synthesis Type
      • 9.3.2.2.3. By Animal Type
      • 9.3.2.2.4. By Therapeutic Category
  • 9.3.3. Colombia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service Type
      • 9.3.3.2.2. By Synthesis Type
      • 9.3.3.2.3. By Animal Type
      • 9.3.3.2.4. By Therapeutic Category

10. Middle East and Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service Type
  • 10.2.2. By Synthesis Type
  • 10.2.3. By Animal Type
  • 10.2.4. By Therapeutic Category
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service Type
      • 10.3.1.2.2. By Synthesis Type
      • 10.3.1.2.3. By Animal Type
      • 10.3.1.2.4. By Therapeutic Category
  • 10.3.2. Saudi Arabia Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service Type
      • 10.3.2.2.2. By Synthesis Type
      • 10.3.2.2.3. By Animal Type
      • 10.3.2.2.4. By Therapeutic Category
  • 10.3.3. UAE Veterinary Active Pharmaceutical Ingredients Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service Type
      • 10.3.3.2.2. By Synthesis Type
      • 10.3.3.2.3. By Animal Type
      • 10.3.3.2.4. By Therapeutic Category

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Zoetis Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Alivira Animal Health Limited
• 14.3. Ofichem Group
• 14.4. Chempro Group
• 14.5. Siflon Group
• 14.6. Qilu Animal Health Products Co., Ltd.
• 14.7. Chemo Holding, S.L
• 14.8. SUAN FARMA S.A.U
• 14.9. MENADIONA
• 14.10. Excel Industries Ltd

15. Strategic Recommendations

16. About Us & Disclaimer